Background: Interim results of the randomized phase II trial of neoadjuvant tislelizumab +/- oral APL-1202 (nitroxoline) revealed promising pathological complete response (pCR) rates and met ...

EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

Among patients with nonmetastatic, muscle-invasive bladder cancer (MIBC), treatment with neoadjuvant cisplatin-based combination chemotherapy (NAC) plus bladder-saving concurrent chemoradiation ...

Bladder Preservation in Muscle-Invasive Bladder Cancer. ... [to neoadjuvant therapy]," study author Daniel Geynisman, MD, of Fox Chase Cancer Center in Philadelphia, told MedPage Today.

Patients were randomly assigned to receive either neoadjuvant mitomycin C or no neoadjuvant therapy (control arm) prior to TURBT. In the experimental arm, patients underwent cystoscopy and tumor ...

In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

A new study published in the British Journal of Urology International found that sarcopenia was linked to increased the risk ...

References: Imfinzi ® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer. News release. AstraZeneca. March 31, 2025 ...

Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may ...

And, with 1063 participants, it is the largest study ever undertaken in muscle-invasive bladder cancer, noted Powles. The patient population had classic muscle-invasive disease (clinical tumor ...

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with almost 17,000 fatalities. A new gene therapy is giving patients more hope of ...